Deanna L. Thorson

Deanna L. Thorson

Auto-generated profile, based on publicly available information

Deanna L. Thorson

Department of Radiology, Feinberg School of Medicine Northwestern University Chicago IL USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in RadioGraphics
Verified
Journal Article
Closed access
CVCamila Lopes Vendrami
Camila Lopes Vendrami
DTDeanna L. Thorson
Deanna L. Thorson
ABAmir A. Borhani
Amir A. Borhani
PMPardeep K. Mittal
Pardeep K. Mittal
NHNancy A. Hammond
Nancy A. Hammond
FMFrank H Miller
Frank H Miller
Pathologic conditions of the biliary system, although common, can be difficult to diagnose clinically. Challenges in biliary imaging include anatomic variants and the dynamic nature of the biliary tract, which can change with age and intervention, blurring the boundaries of normal and abnormal. Choledochal cysts can have numerous appearances and are important to diagnose given the risk of cholangiocarcinoma potentially requiring surgical resection. Choledocholithiasis, the most common cause of biliary dilatation, can be difficult to detect at US and CT, with MRI having the highest sensitivity. However, knowledge of the imaging pitfalls of MRI and MR cholangiopancreatography is crucial to avoid misinterpretation. Newer concepts in biliary tract malignancy include intraductal papillary biliary neoplasms that may develop into cholangiocarcinoma. New paradigms in the classification of cholangiocarcinoma correspond to the wide range of imaging appearances of the disease and have implications for prognosis. Accurately staging cholangiocarcinoma is imperative, given expanding curative options including transplant and more aggressive surgical options. Infections of the biliary tree include acute cholangitis or recurrent pyogenic cholangitis, characterized by obstruction, strictures, and central biliary dilatation. Inflammatory conditions include primary sclerosing cholangitis, which features strictures and fibrosis but can be difficult to differentiate from secondary causes of sclerosing cholangitis, including more recently described entities such as immunoglobulin G4-related sclerosing cholangitis and COVID-19 secondary sclerosing cholangitis. The authors describe a wide variety of benign and malignant biliary tract abnormalities, highlight differentiating features of the cholangitides, provide an approach to interpretation based on the pattern of imaging findings, and discuss pearls and pitfalls of imaging to facilitate accurate diagnosis. ©RSNA, 2024 Supplemental material is available for this article.

12 April 2025 in BJUI Compass
Verified
Journal Article
Open access
DTDeanna Thorson
Deanna Thorson
DBDavide Bova
Davide Bova
MPMaria M. Picken
Maria M. Picken
MQMarcus L. Quek
Marcus L. Quek
GGGopal N. Gupta
Gopal N. Gupta
HPHiten D. Patel
Hiten D. Patel
Objectives: To evaluate the feasibility of using the peak early‐phase enhancement ratio (PEER) of tumour to renal cortex measured on contrast‐enhanced magnetic resonance imaging (MRI) to distinguish between chromophobe renal cell carcinoma (chRCC) and oncocytoma, which are difficult to differentiate on renal mass biopsy.Patients and Methods: A consecutive case–control study was conducted of patients with chRCC or oncocytoma based on surgical pathology (2006–2020). Two radiologists blinded to pathology results independently measured PEER values on MRI for each tumour. PEER values were compared with surgical pathology results.Results: For the 18 renal tumours evaluated, PEER values were higher for the 7 oncocytomas than for the 11 chRCCs (median 1.33 versus 0.55, p < 0.001). Agreement between the image interpreters was high (Pearson's: 0.90). PEER cutoff values ranging from 0.98 to 1.05 provided high performance in identifying chRCC. A PEER cutoff value of ≤1.05 had sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of 100% for the averaged PEER measurements between the two radiologists. High accuracy in identifying chRCC was also achieved for each individual image interpreter using the cutoff value of ≤1.05, with sensitivity of 100%, specificity of 85.7%, PPV of 91.7% and NPV of 100% for radiologist #1 and sensitivity of 90.9%, specificity of 85.7%, PPV of 90.9% and NPV of 85.7% for radiologist #2.Conclusion: Differentiating chRCCs from oncocytomas using PEER measurements obtained from contrast‐enhanced MRI is feasible and reproducible between radiologists. We identified an accurate range for PEER cutoff values (0.98 to 1.05) requiring validation and adjustment in additional cohorts to maintain high sensitivity for detecting chRCC and negative predictive value. Using MRI PEER to evaluate oncocytic tumours with a differential diagnosis of chRCC versus oncocytoma based on biopsy pathology may help avoid unnecessary intervention for oncocytomas.